Market capitalization | $1.62m |
Enterprise Value | $1.98m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 0.18 |
Short interest | 0.83% |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast Altamira Therapeutics Ltd:
1 Analyst has issued a forecast Altamira Therapeutics Ltd:
Dec '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.13 -0.13 |
91%
91%
|
|
EBITDA | -6.73 -6.73 |
55%
55%
|
EBIT (Operating Income) EBIT | -6.87 -6.87 |
55%
55%
|
Net Profit | -4.31 -4.31 |
84%
84%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.
Head office | Bermuda |
CEO | Thomas Meyer |
Employees | 12 |
Founded | 2003 |
Website | www.altamiratherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.